Akademik Veri Yönetim Sistemi
2nd European Sample Preparation e-Conference (EuSP2022), 14 - 16 Mart 2022, ss.1
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. It is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
The aim of our study is initially to develop the polymeric nanoparticulate drug delivery systems of piroxicam which is a chemopreventive active substance and to evaluate the in-vitro characteristics such as entrapment efficiency, surface morphology, in-vitro drug release performance, and DSC studies were performed for the characterization of nanocarriers of piroxicam. For this reason, a novel extraction and HPLC methodology were developed for the determination of piroxicam from its bulk form, and nanoparticulate delivery system. Furthermore, the developed formulation applied to the rats and biological samples such as plasma, liver, heart, spleen, kidney, and lung were analyzed by using the following method.
A
C18 guard column (Restek, Trident Level 3 LC Column Protection System) and an
analytical column (Phenomenex, Kinetex C18 analytical column 150 mm x 4.6 mm
i.d., 5um) were used as a stationary phase with 0.8 ml/min flow rate of
acetonitrile:phosphate buffer (40:60, v/v), the column oven was adjusted to 40°C
and detection wavelength is set to 360 nm. Lornoxicam was chosen as the
internal standard. Salting out extraction strategy was used for the biological
samples was performed with acetonitrile and NaCl.
Calibration curves were constructed for all biological matrices and bulk form and correlation coefficients were higher than 0.999. The novel extraction and separation method were validated for parameters such as selectivity, linearity, LOD, LOQ, precision, accuracy specified in the International Council for Harmonisation guidelines [1].
As a result of the present study, it has been shown that the analysis of piroxicam from the biological samples can be successfully performed and no interferences were observed in any matrix.
Acknowledgments
This work was supported by Ankara
University Scientific Research Projects Coordination (21L0237008).
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. It is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
The aim of our study is initially to develop the polymeric nanoparticulate drug delivery systems of piroxicam which is a chemopreventive active substance and to evaluate the in-vitro characteristics such as entrapment efficiency, surface morphology, in-vitro drug release performance, and DSC studies were performed for the characterization of nanocarriers of piroxicam. For this reason, a novel extraction and HPLC methodology were developed for the determination of piroxicam from its bulk form, and nanoparticulate delivery system. Furthermore, the developed formulation applied to the rats and biological samples such as plasma, liver, heart, spleen, kidney, and lung were analyzed by using the following method.
A
C18 guard column (Restek, Trident Level 3 LC Column Protection System) and an
analytical column (Phenomenex, Kinetex C18 analytical column 150 mm x 4.6 mm
i.d., 5um) were used as a stationary phase with 0.8 ml/min flow rate of
acetonitrile:phosphate buffer (40:60, v/v), the column oven was adjusted to 40°C
and detection wavelength is set to 360 nm. Lornoxicam was chosen as the
internal standard. Salting out extraction strategy was used for the biological
samples was performed with acetonitrile and NaCl.
Calibration curves were constructed for all biological matrices and bulk form and correlation coefficients were higher than 0.999. The novel extraction and separation method were validated for parameters such as selectivity, linearity, LOD, LOQ, precision, accuracy specified in the International Council for Harmonisation guidelines [1].
As a result of the present study, it has been shown that the analysis of piroxicam from the biological samples can be successfully performed and no interferences were observed in any matrix.
Acknowledgments
This work was supported by Ankara
University Scientific Research Projects Coordination (21L0237008).